State Of Alaska, Department Of Revenue Sage Therapeutics, Inc. Transaction History

State Of Alaska, Department Of Revenue

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 Apr 14, 2022	SELL	$30.71 - $45.71 $102,233 - $152,168	-3,329 Closed	0 $0
Q4 2021 Jan 12, 2022	SELL	$37.06 - $47.11 $2,445 - $3,109	-66 Reduced 1.94%	3,329 $141,000
Q3 2021 Oct 07, 2021	SELL	$40.26 - $57.37 $296,877 - $423,046	-7,374 Reduced 68.47%	3,395 $150,000
Q2 2021 Jul 12, 2021	BUY	$54.88 - $79.29 $172,762 - $249,604	3,148 Added 41.31%	10,769 $611,000
Q1 2021 Apr 09, 2021	BUY	$70.65 - $96.76 $538,423 - $737,407	7,621 New	7,621 $570,000
Q3 2019 Oct 02, 2019	SELL	$140.29 - $189.96 $799,653 - $1.08 Million	-5,700 Closed	0 $0
Q2 2019 Jul 23, 2019	BUY	$157.85 - $183.09 $3,157 - $3,661	20 Added 0.35%	5,700 $1.04 Million
Q1 2019 Apr 09, 2019	BUY	$89.33 - $163.65 $6,699 - $12,273	75 Added 1.34%	5,680 $903,000
Q4 2018 Jan 10, 2019	BUY	$81.94 - $139.71 $3,359 - $5,728	41 Added 0.74%	5,605 $536,000
Q3 2018 Oct 09, 2018	BUY	$138.11 - $169.04 $6,076 - $7,437	44 Added 0.8%	5,564 $785,000
Q2 2018 Jul 10, 2018	BUY	$140.36 - $175.76 $774,787 - $970,195	5,520 New	5,520 $864,000

198

46.5M

402K

209K

Ticker SAGE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,422,300
Market Cap $333M
Description
Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...

Get notified when there are updates to the investment portfolio of State Of Alaska, Department Of Revenue, based on Form 13F filings with the SEC.

Stay updated on State Of Alaska, Department Of Revenue with notifications on news.